IP Library Granted Patent US 11,154,565
Granted Patent B2
US 11,154,565 · App. 15/766,746 · Granted Oct 26, 2021

Process for preparing a stable emulsion comprising one or more avermectins

Inventors: Claire Mallard (Mougins, FR); Richard Dugat (Rumilly, FR); Elodie Roger (Cagnes-sur-mer, FR); Ricardo Diaz (Sevrier, FR)
Assignee: Galderma Holding SA
A61K31/7048A01N25/04A01N43/90A61K9/107A61K47/10A61P17/04A61P17/08A61P17/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,565
App. No.
15/766,746
Granted
Oct 26, 2021
Kind
B2
Abstract

A process is described for preparing a stable emulsion that includes at least one avermectin. Also described, is the emulsion thus obtained, especially for use in the treatment of dermatological disorders such as rosacea.

Claims (14)

1. A process of preparing a composition in the form of an emulsion comprising 0.01% to 3% by weight of at least one avermectin, relative to the total weight of the composition, the process comprising, successively:

(a) emulsifying an oily phase and an aqueous phases at a temperature from 60° C. to 75° C.;

(b) cooling the resulting emulsion to a temperature from 48° C. to 55° C.;

(c) adding to the emulsion an active phase comprising the at least one avermectin dissolved in a medium comprising at least one glycol; and

(d) cooling the emulsion to a single temperature selected from 42° C. to 47° C.;

(e) maintaining the temperature in (d) for 10 to 20 minutes; and

(f) cooling the emulsion further to a temperature from 30° C. to 40° C.

2. The process according to claim 1 , wherein the at least one avermectin is selected from the group consisting of ivermectin and optical isomers thereof.

3. The process according to claim 1 , wherein the at least one avermectin is present in an amount from 0.1% to 2% by weight, relative to the total weight of the composition.

4. The process according to claim 1 , wherein the at least one avermectin is present in an amount from 0.5% to 1% by weight, relative to the total weight of the composition.

5. The process according to claim 1 , wherein the emulsifying is performed at 65° C.±2° C.

6. The process of claim 1 , wherein the emulsion has a Brookfield viscosity that, when measured after the emulsion has been stored at room temperature for 7 days immediately after manufacturing, does not vary by more than 10% compared to the Brookfield viscosity measured immediately after manufacturing.

7. The process of claim 6 , wherein the Brookfield viscosity of the emulsion, when measured after the emulsion has been stored at room temperature for 7 days immediately after manufacturing, does not vary by more than 5% compared to the Brookfield viscosity measured immediately after manufacturing.

8. The process of claim 1 , wherein the cooling of (b), (d), and/or (f) of the emulsion is uncontrolled.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057629/0972 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2021
From: GALDERMA SA
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057635/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2020
From: MALLARD, CLAIRE; DUGAT, RICHARD; ROGER, ELODIE; DIAZ, RICARDO
To: GALDERMA S.A.
Reel/Frame 053241/0360 →